Cukor Daniel, Coplan Jeremy, Brown Clinton, Friedman Steven, Newville Howard, Safier Michal, Spielman Lisa A, Peterson Rolf A, Kimmel Paul L
Department of Psychiatry and Behavioral Sciences, SUNY Downstate Medical Center, Brooklyn, NY 11203-2098, USA.
Am J Kidney Dis. 2008 Jul;52(1):128-36. doi: 10.1053/j.ajkd.2008.02.300. Epub 2008 Apr 28.
Anxiety is a complicating comorbid diagnosis in many patients with medical illnesses. In patients with end-stage renal disease (ESRD), anxiety disorders often are perceived to represent symptoms of depression rather than independent conditions and therefore have been relatively understudied in this medical population.
To evaluate the psychosocial impact of anxiety disorders on patients with ESRD, we sought to identify the rates of these disorders in a sample of patients receiving hemodialysis at a single center by using a structured clinical interview. We also compared a commonly used screening measure, the Hospital Anxiety and Depression Scale (HADS), with these clinical diagnoses to determine the measure's criterion validity or ability to predict a psychiatric diagnosis in ESRD populations. Finally, we examined the relationship between anxiety diagnosis and perceptions of quality of life (QOL) and health status.
SETTING & PARTICIPANTS: A sample of 70 randomly selected hemodialysis patients from an urban metropolitan center.
Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I Diagnosis (SCID-I).
HADS and Kidney Disease Quality of Life Short Form.
Using the SCID, 71% of the sample received a DSM-IV Axis I diagnosis, with 45.7% of subjects meeting criteria for an anxiety disorder and 40% meeting criteria for a mood disorder. The concordance between DSM-IV anxiety disorders and anxiety scores acquired by using the HADS was not significant. Thus, although the HADS may provide an acceptable measure of overall "psychic distress" compared against the SCID-I, it has poor predictive power for anxiety diagnoses in patients with ESRD. Additionally, the presence of an anxiety disorder was associated with an overall perceived lower QOL (t = 2.4; P < 0.05).
Single-center study and a population not representative of US demographics.
A substantial proportion of participating patients met criteria for an anxiety disorder. The utility of the HADS as a screening tool for anxiety in patients with ESRD should be questioned. The finding that anxiety disorders negatively impact on QOL and are not merely manifestations of depression in patients with ESRD emphasizes the importance of accurate diagnosis and effective treatment. Strategic options are necessary to improve the diagnosis of anxiety disorders, potentially enhancing QOL and medical outcome in patients with ESRD.
焦虑是许多患有内科疾病患者的一种复杂的共病诊断。在终末期肾病(ESRD)患者中,焦虑症常被认为是抑郁症的症状而非独立病症,因此在这一内科人群中相对较少受到研究。
为评估焦虑症对ESRD患者的心理社会影响,我们试图通过结构化临床访谈确定在一个单一中心接受血液透析的患者样本中这些疾病的发生率。我们还将一种常用的筛查工具——医院焦虑抑郁量表(HADS)与这些临床诊断进行比较,以确定该工具在ESRD人群中的标准效度或预测精神疾病诊断的能力。最后,我们研究了焦虑症诊断与生活质量(QOL)感知和健康状况之间的关系。
从一个城市大都市中心随机选取70名血液透析患者作为样本。
《精神疾病诊断与统计手册》第四版(DSM-IV)轴I诊断的结构化临床访谈(SCID-I)。
使用SCID,71%的样本获得了DSM-IV轴I诊断,45.7%的受试者符合焦虑症标准,40%符合情绪障碍标准。DSM-IV焦虑症与使用HADS获得的焦虑评分之间的一致性不显著。因此,尽管与SCID-I相比,HADS可能为总体“精神痛苦”提供了一种可接受的测量方法,但它对ESRD患者焦虑症诊断的预测能力较差。此外,焦虑症的存在与总体较低的QOL感知相关(t = 2.4;P < 0.05)。
单中心研究且人群不代表美国人口统计学特征。
相当一部分参与研究的患者符合焦虑症标准。HADS作为ESRD患者焦虑症筛查工具的效用值得质疑。焦虑症对ESRD患者的QOL有负面影响且不仅仅是抑郁症表现这一发现强调了准确诊断和有效治疗的重要性。有必要采取策略性选择来改善焦虑症的诊断,这可能会提高ESRD患者的QOL和医疗结局。